{"filing":{"accession_number":"0001193125-26-257684","cik":"0001544227","ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-04","report_date":null,"primary_document":"d91703d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526257684/d91703d8k.htm"},"events":[{"id":3422,"run_id":2995,"accession_number":"0001193125-26-257684","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"Mr. Nicholas Maestas resigned as Chief Financial Officer and Principal Financial Officer effective June 5, 2026, affecting the registrant's financial leadership.","company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","filing_date":"2026-06-04","items":[{"id":4366,"accession_number":"0001193125-26-257684","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Mr. Nicholas Maestas resigned as Chief Financial Officer and Principal Financial Officer effective June 5, 2026. While the filing also discloses the appointment of Mr. Justin Trojanowski as the new Principal Financial Officer, the primary disclosed action centers on the departure of the CFO. The CFO departure is material as it affects the registrant's financial leadership and investor confidence in financial reporting.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:59:44.779815+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":3423,"run_id":2995,"accession_number":"0001193125-26-257684","anchor_item_number":"7.01","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Tempest Therapeutics appointed Drake Richey and John Yee, MD, MPH to its Board of Directors, affecting governance and strategic direction.","company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","filing_date":"2026-06-04","items":[{"id":4367,"accession_number":"0001193125-26-257684","item_number":"7.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of two individuals—Drake Richey and John Yee, MD, MPH—to the Board of Directors of Tempest Therapeutics. This is a clear executive appointment event. Board composition changes are material to investors as they affect governance and strategic direction. The press release title explicitly states \"Appoints Drake Richey and John Yee, MD, MPH to Board of Directors.\"","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:59:44.779815+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4366,"accession_number":"0001193125-26-257684","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Mr. Nicholas Maestas resigned as Chief Financial Officer and Principal Financial Officer effective June 5, 2026. While the filing also discloses the appointment of Mr. Justin Trojanowski as the new Principal Financial Officer, the primary disclosed action centers on the departure of the CFO. The CFO departure is material as it affects the registrant's financial leadership and investor confidence in financial reporting.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:59:44.779815+00:00","company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","filing_date":"2026-06-04"},{"id":4367,"accession_number":"0001193125-26-257684","item_number":"7.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of two individuals—Drake Richey and John Yee, MD, MPH—to the Board of Directors of Tempest Therapeutics. This is a clear executive appointment event. Board composition changes are material to investors as they affect governance and strategic direction. The press release title explicitly states \"Appoints Drake Richey and John Yee, MD, MPH to Board of Directors.\"","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:59:44.779815+00:00","company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","filing_date":"2026-06-04"}]}